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A dioxovanadium(V) complex of vitamin-B6 Schiff base [VO2L] (1) (where H2L·HCl is 3-hydroxy-5-(hydroxymethyl)-
4-(((2-hydroxyphenyl)imino)methyl)-2-methylpyridin-1-ium chloride) has been prepared and structurally characterized. Its 
photo-induced cytotoxicity and mechanism of cell death has been studied. Single crystal X-ray structure shows five-coordinate 
square-pyramidal geometry of the complex having the dianionic O,N,O-donor tridentate vitamin-B6 Schiff base and two  
cis-oriented oxo ligands bound to V(V). DFT study shows the HOMO located on the amino-phenolic moiety, while the LUMO 
is on the protonated aromatic unit, i.e., the pyridiniumphenolate moiety. Vitamin-B6 transporting membrane carrier (VTC) 
pathway seems to be responsible for the higher cellular uptake and activity of the complex into the cervical HeLa and breast 
cancer MCF-7 cells in preference to the normal embryonic fibroblast 3T3 cells. The complex exhibits reactive oxygen species 
(ROS) mediated apoptotic photocytotoxicity in visible light of 400–700 nm in the cancer cells (IC50: ~16 μM), while being 
essentially non-toxic in the dark. Alkaline Comet assay shows damage of the nuclear DNA. 
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Photodynamic therapy (PDT) has emerged as a new 
treatment modality for cancer1-11. PDT being 
selective, damages only the photo-irradiated cancer 
cells with minimal effect to the unexposed normal 
cells. The FDA approved PDT drug is Photofrin 
which on red light activation (632 nm) produces 
singlet oxygen (1O2) as the reactive oxygen species 
(ROS)12-14. Selective activation of Photofrin at  
the tumour site circumvents the side effects 
associated with the widely used platinum(II)  
based chemotherapeutic drugs1,2,12-14. Photofrin, 
however, suffers from several limitations: (i) causing 
hepatotoxicity due to its oxidative degradation to 
bilirubin, (ii) skin photosensitivity for a long period 
due to significant localization on the skin tissues and 
(iii) low selectivity towards cancer cells over  
normal ones1,2,4,5,15. Recent reports have shown  
that photoactive transition metal complexes could be 
the potential alternatives to this drug16-30. The current 
focus in this chemistry is to develop tumour targeting 
photoactive anticancer metal complexes that can 
recognize the intrinsic differences between the 
cancerous and healthy cells and thus minimize the drug 
related side effects31,32. The photoactive complexes 
bearing a tumour recognition moiety is expected to 
improve the selectivity33,34. We have previously shown 
that vitamin-B6 (VB6) conjugated metal complexes 
specifically localize in the tumour cells over their 
normal counterpart35-37. Vitamin-B6 is known for its 
biological importance, involved in a variety of 
metabolic and physiological processes such as lipid, 
glucose and amino acid metabolisms38-40. It is an 
important cofactor in DNA biosynthesis, hence  
has an important role in cellular growth and also  
is a protective factor against various cancers.  
VB6 derivatives are known to inhibit tumorigenesis41. 
Cellular uptake of VB6 is through its transporting 
membrane carrier (VTC) mediated diffusion42,43. Since 
rapidly growing tumour cells demands high dosage of 
VB6 for their survival, the VB6 incorporated metal 
complexes are prone to achieve VTC mediated 
preferential uptake into the cancer cells over the 
normal ones35-37. The present report is based on our 
work on the anticancer potential of a new ternary 
dioxovanadium(V) complex [VO2L] having a VB6 
incorporated Schiff base moiety. Vanadium being 
useful trace element in the biological systems, its 
compounds are used as insulin mimetics and antitumor 
agents as well44-46. While oxovanadium(IV) complexes 
are known for their photo-induced anticancer  
activity, dioxovanadium(V) complexes showing 
similar activity remain virtually unexplored9-11,20,21. 




Besides, the reported dioxovanadium(V) complexes 
show UV-light induced cytotoxicity which is not 
preferred in PDT47,48. 
Herein, we present the synthesis, characterization, 
tumour selective visible light-induced anticancer 
activity of a new dioxovanadium(V) complex [VO2L] 
(1), where H2L·HCl is 3-hydroxy-5-(hydroxymethyl)-
4-(((2-hydroxyphenyl)imino)-methyl)-2-methylpyridin-
1-ium chloride (Fig. 1). The complex has been 
structurally characterized by X-ray crystallography. 
Significant results of this report include: (i) VTC-
mediated uptake of the complex into the cancer cells, 
(ii) apoptotic photo-cytotoxicity in HeLa and MCF-7 
cancer cells (IC50 < 20 µM) in visible light of  
400-700 nm while remaining less toxic in 3T3 normal 
cells and in dark, and, (iii) the photo-activated 
apoptotic cell death resulting from damage to nuclear 
DNA from oxidative cell stress due to generation of 
intracellular ROS on photo-activation. 
 
Materials and Methods 
The reagents and chemicals were procured from 
commercial sources (Sigma-Aldrich, USA) and used as 
such without any further purification. VO(acac)2 
(Hacac, acetylacetone) and pyridoxal hydrochloride 
were purchased from Sigma-Aldrich. Solvents were 
purified following standard literature procedures49. 
Agarose (molecular biology grade), 2,7-dichloro- 
fluoresceindiacetate (DCFDA), propidium iodide (PI), 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), Dulbecco’s modified eagle medium 
(DMEM), and fetal bovine serum (FBS) were obtained 
from Sigma (USA). OxiSelect™ Comet assay kit  
was purchased from Cell Biolabs Inc. The Schiff  
base (H2L·HCl) was prepared following a literature  
report by reacting pyridoxal hydrochloride with  
2-aminophenol in dry methanol at room temperature50.  
Elemental analysis was done by a VarioELcube 
CHNS Elemental analyzer. The solid state IR and  
UV-visible spectra were recorded using Bruker Alpha  
and Perkin-Elmer Spectrum 650 spectrophotometers, 
respectively, at 25 C. Electrospray ionization (ESI) 
mass spectral measurements were made using Agilent 
6538 Ultra High Definition (UHD) accurate Mass-Q-
TOF (LC-HRMS) and Bruker Daltonics make Esquire 
300 Plus ESI mass spectrometers. NMR spectra were 
recorded on a Bruker Avance 400 NMR spectrometer 
(400 MHz). Flow cytometric analysis was done using 
FACS Calibur (Becton Dickinson cell analyser) at FL1 
channel (595 nm). Fluorescence microscopic experiments 
were performed by Apotome.2 fluorescence microscope 
using an oil immersion lens of 63X magnification. 
 
Synthesis of the complex 
Complex 1 of the formulation [VO2L] was prepared 
by reacting an ethanol solution of VO(acac)2 (0.265 g, 
1.0 mmol in 4 mL ethanol) to a hot ethanol solution  
of H2LHCl (0.295 g, 1.0 mmol in 10 mL methanol). 
The solution colour changed from light red to deep  
red. After refluxing for 2 h, the solution was cooled to 
room temperature to obtain a red precipitate of  
the complex. The precipitate was isolated and washed 
with ethanol, chilled methanol, chloroform and finally 
dried over P4O10 under vacuum. 
Yield = 77%. Anal. (%): Calc. for C14H13N2O5V (1): 
C, 49.43; H, 3.85; N, 8.23. Found: C, 49.79; H, 4.06; 
N, 8.11. ESI-MS in MeOH: m/z 614.1125 [M+H]+.  
IR data cm−1: 1610 s (C=N), 1586 m, 1487 w,  
1377 m, 1266 s, 1155 m, 968 s (V=O), 810 m, 540 m, 
462 m (s, strong; m, medium; w, weak). UV-visible  
in DMF [λmax/nm (ε/M−1 cm−1)]: 465 (23700),  
290 (74200). Molar conductivity in DMF at 298 K  
[ΛM/S m2 M−1]: 12.  
 
X-ray crystallographic studies 
Crystals of complex 1MeOH were grown via slow 
evaporation of a methanolic solution of the complex 
over four days. A crystal of 0.44×0.4×0.2 mm3 size was 
mounted on a glass fibre with epoxy cement. All 
geometric and intensity data were collected at room 
temperature using an automated Bruker Smart Apex 
CCD diffractometer equipped with a fine focus  
1.75 kW sealed tube Mo-Kα X-ray source (λ = 0.71073 Å) 
with increasing ω (width of 0.3° per frame) at  
a scan speed of 5 sec per frame. Intensity data were 
collected using ω-2θ scan mode and due corrections 
were made for the Lorentz–polarization effects  
and for absorption51. Patterson and Fourier techniques 
were used to solve the structure and refinement was 
 
 
Fig. 1 — Structure of the dioxovanadium(V) [VO2L](1) and the 
vitamin-B6 Schiff base complex. 




done by full matrix least squares method using 
SHELXL-2013 present in the WinGx programs  
(ver. 1.63.04a)52,53. The hydrogen atoms of the complex 
were placed in their calculated positions and refined in 
the riding mode. The hydrogen atom attached to the 
pyridoxal nitrogen atom was located in the difference 
Fourier map. The final refinement included atomic 
positions for all the atoms, anisotropic thermal 
parameters for all the non-hydrogen atoms and 
isotropic thermal parameters for all the hydrogen 
atoms. Perspective view of the complex was  
obtained by ORTEP54. Crystallographic data and the 
structure refinement parameters for the complex are 
given in Table 1. 
 
Cell viability (MTT) assay 
Approximately 1.0×104 HeLa cervical cancer, 
MCF-7 breast cancer and 3T3 embryonic fibroblast 
normal cells were plated in each well of a 96-well  
cell culture plate in DMEM cell culture medium 
supplemented with 10% fetal bovine serum  
(10% DMEM) and cultured for 12 h. The assay was 
performed based upon standard protocols9-11,17-19,23-25. 
The complex was dissolved in DMSO-10% DMEM 
(1:99 v/v) and was added to the cells at various 
concentrations. Incubation was done for 4 h in the dark 
with subsequent photo-irradiation for 1 h in phosphate 
buffer saline (PBS) under visible light of 400-700 nm 
using Luzchem Photoreactor (model LZC-1, Ontario, 
Canada) assembled with Sylvania make 8 white 
fluorescent tubes giving an overall fluence rate of 
2.4 mW cm-2 (total dose of 10 J cm-2). PBS was 
replaced with 10% DMEM after photo exposure. 
Incubation was continued in the dark for further  
20 h. A 25 μL of 5 mg mL-1 of MTT was added to  
each well and incubated for 3 h. The culture medium 
was discarded and 100 μL of DMSO was added  
to dissolve the formazan crystals. The intensity of 
formazan was estimated from its absorbance at 540 nm 
in DMSO using an ELISA microplate reader (BioRad, 
Hercules, CA, USA). The IC50 values were determined 
using nonlinear regression analysis method by  
plotting “log(inhibitor) vs. normalized response 
(variable slope)” using GraphPad Prism version 5.155. 
To ascertain that the VTC mediated diffusion pathway 
was responsible for the cellular uptake of the complex, 
HeLa cells were first incubated with 4 mM vitamin-B6 
for 45 min with subsequent addition of the complex for 
the MTT assay following a similar protocol as 
described above. 
 
DCFDA assay for ROS 
DCFDA assay was carried out to detect any 
generation of intracellular reactive oxygen species 
(ROS) by the complex upon visible light (400-700 nm) 
irradiation. HeLa cells were incubated with 20 µM of 
the complex for 4 h followed by photo-exposure to 
visible light for 1 h in phosphate buffer saline (PBS). 
Cells were then harvested by trypsinization and single 
cell suspension of 1.0×106 cells per mL was prepared. 
The suspension was then treated with 10 μM DCFDA 
(in DMSO) and kept in the dark for 10 min at 25 C. 
Flow cytometric analysis was performed to obtain the 
distribution of the cells stained with DCFDA56. 
 
Annexin-V/PI binding assay 
To ascertain the pathway of photo-induced cell 
death by complex 1, approximately 4.0×105 HeLa  
cells per mL were incubated with the complex (20 μM) 
Table 1 — Selected crystallographic data and structure refinement 
parameters for complex 1MeOH 
Emp. formula C15 H17 N2 O6 V 
Formula wt. (g mol-1) 372.25 
Crystal system Monoclinic 
Space group P 21/c 
a (Å) 7.5141(6) 
b (Å) 14.1457(11) 
c (Å) 14.4731(11) 
 =  (°) 90 
 (°) 94.078(3)° 
V (Å3) 1534.5(2) 
Z 4 
T (K) 296(2) 
calc(g cm-3) 1.611 
 (Å) (Mo-K) 0.71073 
 (mm-1) 0.682 
Data/restraints/parameters 4692/ 0/ 285 
F(000) 768 
Crystal size 0.44×0.40×0.20 mm3 
 (data collection) 2.718 to 30.646° 
Limiting indices –10≤h<=10, –20≤k<=20,  
–19≤l<=20 
Reflections collected 32749 
Ind. reflections 4742 [R(int) = 0.0462] 
Completeness to  
 = 25.242° 
99.8% 
Max. and min. transmission 0.869 and 0.741 
Goodness-of-fit on F2 0.903 
Final R indices [I > 2(I)] R1 = 0.0314, wR2 = 0.0857 
R indices (all data) R1 = 0.0385, wR2 = 0.0921 
Largest diff. peak and  
hole (e Å3) 
0.490 and  
–0.261 




in 10% DMEM for 4 h in the dark, followed by 
exposure to visible light (400-700 nm, dose 10 J cm-2) 
for 1 h. The cells were then cultured for 18 h in 
complete medium under darkness, harvested and 
washed twice with chilled PBS. The cells were  
re-suspended in 100 µL Annexin-V binding buffer 
(100 mmol HEPES/ NaOH, pH 7.4 containing  
140 mmol NaCl and 2.5 mmol CaCl2), stained  
with Annexin-V FITC and propidium iodide (PI), and 
incubated for 15 min at 25 C in the dark. A 400 μL of 
binding buffer was added to the cells after incubation 
and analysed immediately by flow cytometry57. 
 
Comet assay 
To detect the photo-induced DNA damaging ability 
of the complex at the single cell level, comet assay was 
performed. Around 1.5×104 HeLa cells were incubated 
with 30 µM of the complex for 4h in the dark followed 
by 1h of light irradiation (visible light of 400-700 nm). 
Cells were subsequently harvested and re-suspended  
in 75 μL of 0.5% low melting point agarose. The  
cell suspension was spread over agarose coated 
microscopic slides and allowed to dry. Successively, 
the slides were put into cold lysis solution (2.5 M 
sodium chloride, 100 mmol EDTA, 10 mmol Tris-HCl, 
pH = 10, 1% Triton X100, 10% DMSO) at 4°C for 3 h. 
After lysis, slides were kept in electrophoresis  
buffer (300 mmol NaOH and 1 mmol EDTA, pH = 13) 
at 4 °C. They were incubated for 30 min in the buffer 
for DNA unwinding followed by electrophoresis  
in the same buffer at 25 V, 300 mA, 4 °C for 45 min. 
Slides were neutralized in 0.4 M Tris-HCl (pH = 7.5) 
and stained with Vista Green DNA Dye for  
15 min. Images were acquired using Apotome.2 
fluorescence microscope (Carl Zeiss, Germany) using 
a FITC (Fluorescein IsothioCyanate) filter20,21.  
 
Results and Discussion 
 
Synthesis and general aspects 
The complex was prepared from the reaction of 
vitamin-B6 Schiff base (H2LHCl) with VO(acac)2 in 
MeOH. The complex was characterized from the 
spectral and analytical data. ESI-MS spectrum of the 
diamagnetic complex in MeOH gave a single peak at 
m/z value of 341.1939 corresponding to [M+H]+.  
The complex in DMF displayed a broad band near  
465 nm assignable to PhO− → V(V) ligand-to-metal 
charge transfer (LMCT) transition (Fig. 2)58. The band 
near 290 nm was assigned to the ligand-based π→π* 
transition59. The solid state FT-IR spectra displayed 
characteristic IR peaks at 968 cm−1 and 1614 cm−1  
for the V=O and the co-ordinated C=N stretching 
vibrations, respectively. Molar conductance value of 
∼12 S m2 M−1 in DMF suggests the non-electrolytic 
nature of the complex60,61. The complex showed  
good solubility in DMSO, DMF, MeCN and MeOH; 
moderate solubility in ethanol, water and poor 
solubility in hydrocarbons. The complex was stable in 
both solid and solution phases. The complex is redox 
active showing cyclic voltammetric responses 
involving the metal center and the ligands in 20% 
aqueous DMF with 0.1 M TBAP as the supporting 
electrolyte. The cathodic scan showed two responses 
with Ef values of –0.7 V (∆Ep = 270 mV) and –1.2 V 
(∆Ep= 130 mV). The data agree well with those of other 
reported dioxovanadium(V) complexes47,48. 
 
Crystal structure of the complex 
Complex 1 was characterized by single crystal  
X-ray diffraction method. It crystallizes in P21/c space 
group of the monoclinic crystal system with four 
molecules in the unit cell and MeOH as the lattice 
solvent molecule. A perspective view of the complex 
is shown in Fig. 3. The molecular structure showed a 
discrete mononuclear penta-coordinated VVNO4 
coordination geometry where vanadium atom is 
coordinated to the chelating O,N,O-donor vitamin-B6 
Schiff base. It has a cis-oriented dioxovanadium(V) 
moiety. The V=O bond lengths are 1.6180(10) and 
1.6571(9) Å. The V–O distances involving the phenolato 
moieties of the Schiff base are 1.9187(9) and 1.9356(9) 
Å. The V–N bond distance of 2.2138(11) Å is  
long due to trans effect of the V=O moiety. Selected 
bond lengths and angles data are presented in  
Table 2. The structure showed the presence of  
MeOH as the solvent of crystallization. The solid-state 
 
 
Fig. 2 — Absorption spectrum of complex 1 in DMF. 
 




structure of complex 1 shows chemically important 
hydrogen bonding interactions between the solvent and 
the complex. The molecules form dimeric stacked 
structure assisted with hydrogen-bonding interactions 
with the MeOH molecules (Fig. 4). The N-H protons 
of the pyridinium units also form interactions with the 
V=O bonds. This is also in support with the theoretical 
data obtained from the DFT calculations showing the 
presence of a positive surface potential on the 
pyridinium moiety and negative surface potential on 
the V=O bonds.  
 
Theoretical studies 
Geometry optimization calculations were performed 
using coordinates from the X-ray structure by B3LYP 
method and 6-31G(d) basis set for all the atoms to 
understand the electronic structure of the complex62-66. 
The energy optimized structure of the complex showed 
that the vanadium(V) centre is coordinated to the 
chelating O,N,O-donor vitamin-B6 Schiff base and 
two oxo atoms giving a distorted square-pyramidal 
coordination geometry as observed in the crystal 
structure with similar bonding parameters. As shown 
in Fig. 5, the HOMO is located on the amino-phenolic 
moiety whereas the LUMO is located on the protonated 
aromatic part, i.e. the pyridiniumphenolate moiety 
which could facilitate charge-transfer upon electronic 
excitation of the molecule thus giving the possibility  
of having the PDT activity. The pyridinium moiety  
can be regarded as an electron acceptor unit whereas 
the amino-phenolic moiety is an electron rich system. 
This is evident from the electrostatic potential surface 
of the complex, shown in Fig. 6. 
 
Photocytotoxicity 
The ability of the complex to inhibit the cellular 
growth and induce cell death upon visible light-
activation with 400-700 nm broad band light in human 
cervical cancer HeLa, breast cancer MCF-7 and normal 
fibroblast 3T3 cells was studied by MTT assay67. The 
choice of the excitation wavelength is based on the 
presence of a ligand→metal charge transfer (LMCT) 
 
 
Fig. 3 — An ORTEP view of the complex is shown with the atom 
numbering for the metal and hetero atoms.  
 
Table 2 – Selected bond distances (Å) and angles () for 1MeOHa 
V(1)-O(2)  1.6180(10) 
V(1)-O(3)  1.6571(9) 
V(1)-O(4)  1.9187(9) 
V(1)-O(1)  1.9356(9) 
V(1)-N(1)  2.2138(11) 















Fig. 4 — Intermolecular interaction between the complex and the 




Fig. 5 — The frontier molecular orbitals of the complex. 
 




band near 460 nm in the electronic spectrum of the 
complex. The complex showed light induced  
reduction in the HeLa and MCF-7 cells viability in a  
dose-dependent manner giving the IC50 values of 
15.6±1.2 µM in HeLa and 18.8±1.4 µM in MCF-7 
cells, while being less toxic in the dark (IC50 > 75 µM) 
even after 72 h of incubation (Fig. 7). The complex is 
less active against normal 3T3 cells compared to the 
cancer cells (IC50: 65.7±2.8 µM in light and >100 µM 
in the dark for 3T3 cells). This could be due to lower 
cellular uptake of the complex in 3T3 normal cells 
considering the facts that (i) rapidly proliferating 
cancer cells have high demand for VB6 compared to 
the normal cells and (ii) the presence of high density of 
VB6 transporting membrane carrier (VTC) in cancer 
cells over the normal ones. The IC50 value of the 
complex upon light exposure increased to 56.4±3.6 µM 
when it is pre-incubated with 4.0 mmol vitamin-B6. 
This suggests that uptake of this complex is mainly via 
VTC mediated diffusion pathway. The results are of 
importance considering tumour targeting potential and 
significant PDT activity of this complex compared to 
other known dioxovanadium(V) complexes47,48. 
 
DCFDA assay for ROS  
Reactive oxygen species (ROS) plays a crucial 
role to generate oxidative stress in cells inducing 
cell apoptosis by the photoactive metal complexes4,8,14. 
Hence, 2’,7’-dichlorofluorescein diacetate (DCFDA) 
assay was carried out to detect any photo-assisted 
generation of intracellular ROS in the presence of 
the complex. DCFDA is a non-fluorescent and  
cell permeable fluorogenic probe. Its cleavage by 
intracellular esterases and oxidation by ROS 
generates green fluorescent DCF with an emission 
maximum at ∼525 nm which can be detected by 
FACS analysis68. HeLa cells treated with the 
complex and kept in dark did not show any 
generation of DCF. Whereas, a similar experiment 
in the presence of visible light (400–700 nm) 
showed significant shift of the emission band 
towards the right indicating ROS generation. This 
enhancement in the intensity of intracellular 
emission results from DCF formed from DCFDA 
on oxidation by ROS (Fig. 8). It can be inferred that 
the light triggered ROS generation induces 
oxidative cell stress resulting in the damage of 
nuclear DNA and cellular apoptosis.  
 
 
Fig. 6 — Electrostatic potential surface of the complex (isovalue = 
0.004) as obtained from the DFT optimized geometry. 
  
 
Fig. 7 — Photo-induced cytotoxicity of complex 1 in cervical 
HeLa, breast cancer MCF-7 and 3T3 normal cells on 4 h incubation 
in the dark (black bar) followed by photo-irradiation with visible 




Fig. 8 — FACS analysis for ROS generation by complex 1
performed using DCFDA assay. Generation of ROS is 
highlighted by the shift in the fluorescence intensity in HeLa 
cells treated with the complex under different experimental 
conditions; (i) cells alone, (ii) cells+DCFDA, (iii) cells+ 
DCFDA+1 (dark) and (iv) cells+DCFDA+1 (light). 
 




Annexin-V-FITC/PI assay with the green 
emitting fluorogenic probe that binds to 
phosphatidylserine was done to study the nature of 
cell death. Annexin-V is a calcium ion dependent 
phospholipid binding protein. Apoptosis mediated 
cell death results phosphatidylserine remaining in 
the inner leaflet of lipid bilayer in healthy cells  
and comes out at outer leaflet due to a change in 
the phospholipid asymmetry. This morphological 
change can be detected using Annexin-V-FITC 
probe. The red emitting nuclear staining propidium 
iodide dye was used as a secondary marker. Cells 
at early apoptotic stage can be identified as single 
positive population for annexin-V-FITC, while 
necrotic cell population can be stained by PI.  
The double positive cell population is assigned  
to the late apoptotic cells with compromised cell 
membrane. To examine the cellular apoptosis upon 
visible light irradiation, HeLa cells were treated 
with the complex (20 μM, 4 h incubation) followed 
by photo-irradiation using visible light. Nearly 
32% of the cells were found to be in an early 
apoptotic stage and ~10% of the cells were in a late 
apoptotic stage. Necrotic population was found to 
be significantly low suggesting an overall 
apoptotic mode of photo-induced cell death.  
The complex did not induce any significant cell 
death when kept in the dark.  
 
Damage of nuclear DNA: Comet assay 
Alkaline comet assay was used to visualize any 
damage of the nuclear DNA. This method is generally 
used to detect any DNA damage at the single cell level. 
Upon agarose gel electrophoresis, the damaged DNA 
showed formation of a tail, as the damaged DNA 
migrate faster compared to the undamaged DNA. 
When the complex was photo-activated in the HeLa 
cells and the DNA was analysed by alkaline comet 
assay, a significant increase in the tail length was 
observed compared to the complex untreated control or 
the dark control (Fig. 9). The Comet assay results 
suggest that single cell’s DNA underwent degradation 
as a consequence of the visible light (400-700 nm) 
triggered apoptosis induced by the complex. 
 
Conclusions 
A new dioxovanadium(V) complex of vitamin-B6 
Schiff base was prepared as a tumour targeting, visible 
light-induced photocytotoxic agent. The structurally 
characterized complex showed significant cell death in 
visible light (400-700 nm) targeting primarily the 
cancer cells, while being less toxic in the dark or  
in the 3T3 normal cells. The complex showed cellular 
internalization by VTC-mediated diffusion pathway. 
The complex on photo-activation induced cellular 
apoptosis by forming intracellular reactive oxygen 
species while remaining inactive under darkness as 
evidenced from the Annexin V-FITC/PI and DCFDA 
data. While oxovanadium(IV) complexes are known 
for their visible light-induced anticancer activity, 
dioxovanadium(V) complexes showing similar  
activity are virtually unknown in the chemistry of 
photodynamic therapy. The results are of significance 
considering the ability of the complex with a VO2+ 
moiety to act as potential DNA crosslinking agent  
on metal reduction and on photo-activation akin to 




The crystallographic data have been deposited  
with the Cambridge Crystallographic Data Centre  
under CCDC reference number 1508677 for 1∙MeOH.  
The copies of this information may be obtained free of 
 
 
Fig. 9 — A representative image showing increase in the relative tail length by complex 1 upon photo-irradiation with visible light 
(400–700 nm) in the modified alkaline comet assay in HeLa cells. Panel (a) is the complex untreated control. Panel (b) shows the complex 
in darkness. Panel (c) is for the complex after photo-irradiation using visible light.  
 




charge from the Director, CCDC, 12 Union road, 
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